Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
1.290
+0.100 (8.40%)
Jun 6, 2025, 4:00 PM - Market closed
Nexalin Technology Revenue
Nexalin Technology had revenue of $41.02K in the quarter ending March 31, 2025, a decrease of -47.87%. This brings the company's revenue in the last twelve months to $131.07K, down -17.50% year-over-year. In the year 2024, Nexalin Technology had annual revenue of $168.72K with 52.35% growth.
Revenue (ttm)
$131.07K
Revenue Growth
-17.50%
P/S Ratio
105.15
Revenue / Employee
$21,844
Employees
6
Market Cap
22.16M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NXL News
- 9 days ago - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3 - GlobeNewsWire
- 24 days ago - Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data - GlobeNewsWire
- 4 weeks ago - Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering - GlobeNewsWire
- 4 weeks ago - Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback - GlobeNewsWire
- 6 weeks ago - Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia - GlobeNewsWire
- 6 weeks ago - Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management - GlobeNewsWire
- 6 weeks ago - Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices - GlobeNewsWire